Twenty years of therapy for HIV-1 infection

Nature Medicine

Volumn 9, Issue 7, 2003, Pages 867-873

  Pomerantz, Roger J ^a   Horn, David L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIDEX EC; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANTI-HIV AGENTS; DEVELOPING COUNTRIES; GUIDELINES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0037624182     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0703-867     Document Type: Review

References (87)

1. Rothenberg, R. et al. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N. Engl. J. Med. 317, 1297-1302 (1987).
2. Pneumocystis pneumonia - Los Angeles. MMWR Morb. Mortal. Wkly. Rep. 30, 250-252 (1981).
3. Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
4. Gallo, R.C. et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220, 865-867 (1983).
5. Silberner, J. AIDS blood screen approved. Sci. News 127, 148 (1985).
6. Ezzell, C. AIDS drug gets green light. Nature 329, 751 (1987).
7. Furman, P.A. & Barry, D.W. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am. J. Med. 85, 176-181 (1988).
8. Richman, D.D. HIV chemotherapy. Nature 410, 995-1001 (2001).
9. Gershon, D. Green light for ddl. Nature 353. 589 (1991).
10. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 343, 871-881 (1994).
11. Volberding, P.A. et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N. Engl. J. Med. 333, 401-407 (1995).
12. Update: Mortality attributable to HIV infection among persons aged 25-44 years - United States, 1994. MMWR Morb. Mortal. Wkly. Rep. 45, 121-125 (1996).
13. Connor, E.M. et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 331, 1173-1180 (1994).
14. Venaud, S. et al. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication. Res. Virol. 143, 311-319 (1992).
15. Dorsey, B.D. et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37, 3443-3451 (1994).
16. Vacca, J.P. et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91, 4096-4100 (1994).
17. Hammer, S.M. et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733 (1997).
18. Hirsch, M. et al. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J. Infect. Dis. 180, 659-665 (1999).
19. Gulick, R.M. et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 133, 35-39 (2000).
20. 3: disease progression, treatment durability, and drug toxicity. Clin. Infect. Dis. 36, 812-815 (2003)
21. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
22. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
23. Nolte, F.S. Impact of viral load testing on patient care. Arch. Pathol. Lab. Med. 123, 1011-1014 (1999).
24. Mellors, J.W. et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126, 946-954 (1997).
25. Staszewski, S. et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 341, 1865-1873 (1999).
26. Saag, M.S. et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N. Engl. J. Med. 329, 1065-1072 (1993).
27. DAIDS, N. Trizivir compared to efavirenz plus combivir: 48 weeks interim study results from ACTG 5095. (Center for Disease Control and Prevention, Atlanta, 2003).
28. Carr, A., Miller, J., Law, M. & Cooper, D.A. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, F25-F32 (2000).
29. Carr, A. et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353, 2093-2099 (1999).
30. Safrin, S. & Grunfeld, C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 13, 2493-2505 (1999).
31. Carr, A. et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51-F58 (1998).
32. Bangsberg, D.R. et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15, 1181-1183 (2001).
33. Bangsberg, D.R. et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14, 357-366 (2000).
34. Young, B. et al. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J. Acquir. Immune Defic. Syndr. 31, 478-482 (2002).
35. Cardiello, P.G. et al. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. J. Acquir. Immune Defic. Syndr, 32, 375-379 (2003).
36. Cvetkovic, R.S. & Goa, K.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63, 769-802 (2003).
37. AIDS - United States, 2000. MMWR Morb. Mortal. Wkly. Rep. 51, 592-595 (2002).
38. Sendi, P., Palmer, A.J., Gafni, A. & Battegay, M. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 19, 709-713 (2001).
39. Gallant, J.E. Strategies for long-term success in the treatment of HIV infection. JAMA 283, 1329-1334 (2000).
40. Hirsch, M.S. et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283, 2417-2426 (2000).
41. Shafer, R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15, 247-277 (2002).
42. Durant, J. et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353, 2195-2199 (1999).
43. Baxter, J. et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14, F83-93 (2000).
44. Pomerantz, R.J. Primary HIV-1 resistance: a new phase in the epidemic? JAMA 282, 1177-1179 (1999).
45. Little, S.J. et al. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347, 385-394 (2002).
46. Haggerty, S. & Stevenson, M. Predominance of distinct viral genotypes in brain and lymph node compartments of HIV-1-infected individuals. Viral Immunol. 4, 123-131 (1991).
47. Zhu, T. et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J. Virol. 70, 3098-3107 (1996).
48. Overbaugh, J., Anderson, R.J., Ndinya-Achola, J.O. & Kreiss, J.K. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res. Hum. Retroviruses 12, 107-115 (1996).
49. Zhang, H. et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N. Engl. J. Med. 339, 1803-1809 (1998).
50. Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
51. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
52. Pomerantz, R.J. Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. AIDS 15, 1201-1211 (2001).
53. Dornadula, G. et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282, 1627-1632 (1999).
54. Dornadula, G. et al. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J. Infect. Dis. 183, 1682-1687 (2001).
55. Kulkosky, J. et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186, 1403-1411 (2002).
56. Kulkosky, J. et al. Genotypic alteration of HAART-persistant HIV-1 reservoirs in vivo. Virology (in the press).
57. Kulkosky, J. & Pomerantz, R.J. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. Clin. Infect. Dis. 35, 1520-1526 (2002).
58. Pomerantz, R.J. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin. Infect. Dis. 34, 91-97 (2002).
59. Li, T.S. et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351, 1682-1686 (1998).
60. Autran, B. et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112-116 (1997).
61. Dybul, M. et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm. Rep. 51, 1-55 (2002).
62. Ho, D.D. Time to hit HIV, early and hard. N. Engl. J. Med. 333, 450-451 (1995).
63. Palella, F.J. et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. 138, 620-626 (2003).
64. Minkoff, H. Human immunodeficiency virus infection in pregnancy. Obstet. Gynecol. 101, 797-810 (2003).
65. Lalezari, J.P. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003).
66. Kilby, J.M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302-1307 (1998).
67. Kilby, J.M. et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retroviruses 18, 685-693 (2002).
68. Gulick, R.M. New antiretroviral drugs. Clin. Microbiol. Infect. 9, 186-193 (2003).
69. Farmer, P. The major infectious diseases in the world - to treat or not to treat? N. Engl. J. Med. 345, 208-210 (2001).
70. Bozzette, S.A. et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N. Engl. J. Med. 339, 1897-1904 (1998).
71. Hellinger, F.J. & Fleishman, J.A. Estimating the national cost of treating people with HIV disease: patient, payer, and provider data. J. Acquir. Immune Defic. Syndr. 24, 182-188 (2000).
72. Dybul, M. Structured treatment interruption: approaches and risks. Curr. Infect. Dis. Rep. 4, 175-180 (2002).
73. Garcia, F. et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15, F29-F40 (2001).
74. Hardy, G.A., Imami, N. & Gotch, F.M. Improving HIV-specific immune responses in HIV-infected patients. J. HIV Ther. 7, 40-45 (2002).
75. Caulfield, M.J. et al. Sustained peptide-specific γ interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. J. Virol. 76, 10038-10043 (2002).
76. Pantaleo, G. et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-216 (1995).
77. Rosenberg, E.S. et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
78. Frankel, A.D. & Young, J.A. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67, 1-25 (1998).
79. Grobler, J.A. et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 99, 6661-6666 (2002).
80. Baba, M. et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96, 5698-5703 (1999).
81. Donzella, G.A. et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4, 72-77 (1998).
82. De Clercq, E. New anti-HIV agents and targets. Med. Res. Rev. 22, 531-565 (2002).
83. Yang, B. et al. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 278, 6596-6602 (2003).
84. Gaddis, N.C., Chertova, E., Sheehy, A.M., Henderson, L.E. & Malim, M.H. Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J. Virol. 77, 5810-5820 (2003).
85. Sheehy, A.M., Gaddis, N.C., Choi, J.D. & Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
86. Alexander, L., Aquino-DeJesus, M.J., Chan, M. & Andiman, W.A. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J. Virol. 76, 10533-10539 (2002).
87. Turner, B.G. & Summers, M.F. Structural biology of HIV. J. Mol. Biol. 285, 1-32 (1999).